InspireMD (NYSE:NSPR) Director Paul Stuka Acquires 65,626 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka bought 65,626 shares of InspireMD stock in a transaction dated Friday, May 8th. The shares were bought at an average cost of $1.16 per share, for a total transaction of $76,126.16. Following the completion of the acquisition, the director owned 622,871 shares in the company, valued at $722,530.36. This represents a 11.78% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka acquired 10,000 shares of InspireMD stock. The stock was purchased at an average cost of $1.19 per share, for a total transaction of $11,900.00.
• On Thursday, May 7th, Paul Stuka bought 6,378 shares of InspireMD stock. The stock was acquired at an average price of $1.15 per share, for a total transaction of $7,334.70.
• On Wednesday, May 6th, Paul Stuka bought 1,517 shares of InspireMD stock. The stock was bought at an average price of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Stock Down 4.0%

Shares of NSPR stock opened at $1.20 on Wednesday. The stock’s fifty day simple moving average is $1.47 and its 200 day simple moving average is $1.73. InspireMD, Inc. has a twelve month low of $1.02 and a twelve month high of $2.93. The firm has a market capitalization of $56.21 million, a P/E ratio of -1.60 and a beta of 0.82.

Institutional Trading of InspireMD

A number of hedge funds and other institutional investors have recently made changes to their positions in NSPR. Rosalind Advisors Inc. grew its position in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after acquiring an additional 1,616,644 shares in the last quarter. Nantahala Capital Management LLC grew its position in InspireMD by 45.7% during the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after acquiring an additional 1,058,467 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of InspireMD by 27.9% in the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock valued at $5,649,000 after purchasing an additional 692,247 shares in the last quarter. Orbimed Advisors LLC lifted its stake in InspireMD by 46.9% in the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after purchasing an additional 1,000,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in shares of InspireMD by 97.6% during the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after buying an additional 1,205,328 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on NSPR. Maxim Group began coverage on shares of InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Lake Street Capital set a $4.00 target price on shares of InspireMD in a report on Monday, May 4th. Finally, Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.